AP2014008096A0 - Bicyclically substituted uracils and the use thereof - Google Patents

Bicyclically substituted uracils and the use thereof

Info

Publication number
AP2014008096A0
AP2014008096A0 AP2014008096A AP2014008096A AP2014008096A0 AP 2014008096 A0 AP2014008096 A0 AP 2014008096A0 AP 2014008096 A AP2014008096 A AP 2014008096A AP 2014008096 A AP2014008096 A AP 2014008096A AP 2014008096 A0 AP2014008096 A0 AP 2014008096A0
Authority
AP
ARIPO
Prior art keywords
substituted uracils
bicyclically substituted
bicyclically
uracils
substituted
Prior art date
Application number
AP2014008096A
Other languages
English (en)
Inventor
Katja Zimmermann
Fer Martina Sch
Jens Ackerstaff
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of AP2014008096A0 publication Critical patent/AP2014008096A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AP2014008096A 2012-05-09 2013-05-03 Bicyclically substituted uracils and the use thereof AP2014008096A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12167231 2012-05-09
PCT/EP2013/059286 WO2013167495A1 (de) 2012-05-09 2013-05-03 Bicyclisch-substituierte uracile und ihre verwendung

Publications (1)

Publication Number Publication Date
AP2014008096A0 true AP2014008096A0 (en) 2014-12-31

Family

ID=48289199

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2014008096A AP2014008096A0 (en) 2012-05-09 2013-05-03 Bicyclically substituted uracils and the use thereof

Country Status (44)

Country Link
US (5) US9481672B2 (hr)
EP (2) EP3045456B1 (hr)
JP (2) JP6141414B2 (hr)
KR (1) KR102083281B1 (hr)
CN (2) CN104395310B (hr)
AP (1) AP2014008096A0 (hr)
AR (1) AR090994A1 (hr)
AU (2) AU2013258223B2 (hr)
BR (1) BR112014028086B1 (hr)
CA (1) CA2872906C (hr)
CL (1) CL2014003031A1 (hr)
CO (1) CO7131375A2 (hr)
CR (1) CR20140513A (hr)
CU (1) CU20140129A7 (hr)
CY (2) CY1118900T1 (hr)
DK (2) DK2847190T3 (hr)
DO (1) DOP2014000255A (hr)
EA (2) EA030383B9 (hr)
EC (1) ECSP14026138A (hr)
ES (2) ES2581537T3 (hr)
HK (1) HK1202873A1 (hr)
HR (2) HRP20160796T1 (hr)
HU (2) HUE035462T2 (hr)
IL (2) IL235438A (hr)
JO (1) JO3290B1 (hr)
LT (1) LT3045456T (hr)
MX (2) MX367599B (hr)
MY (1) MY181828A (hr)
NO (1) NO3045456T3 (hr)
NZ (1) NZ701700A (hr)
PE (1) PE20142301A1 (hr)
PH (1) PH12014502496B1 (hr)
PL (2) PL3045456T3 (hr)
PT (2) PT3045456T (hr)
RS (2) RS54901B1 (hr)
SA (1) SA113340533B1 (hr)
SG (1) SG10202003175QA (hr)
SI (2) SI3045456T1 (hr)
TN (1) TN2014000470A1 (hr)
TW (2) TWI635085B (hr)
UA (1) UA112897C2 (hr)
UY (1) UY34797A (hr)
WO (1) WO2013167495A1 (hr)
ZA (1) ZA201408146B (hr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112897C2 (uk) * 2012-05-09 2016-11-10 Байєр Фарма Акцієнгезелльшафт Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань
CN105980381A (zh) * 2013-11-08 2016-09-28 拜耳医药股份有限公司 取代的尿嘧啶及其用途
US20160287599A1 (en) * 2013-11-08 2016-10-06 Bayer Pharma Aktiengesellschaft Substituted 1,2,4-triazine-3,5-diones and the use thereof as chymase inhibitors
LT3066097T (lt) * 2013-11-08 2018-02-12 Bayer Pharma Aktiengesellschaft 1-(3-metil-2-okso-2,3-dihidro-1,3-benzoksazol-6-il)-2,4-diokso-3-[(1r)-4-(trifluormetil)-2,3-dihidro-1h-inden-1-il]-1,2,3,4-tetrahidropirimidin-5-karboksirūgšties druskos
US9695131B2 (en) * 2013-11-08 2017-07-04 Bayer Pharma Aktiengesellschaft Substituted uracils as chymase inhibitors
WO2017162661A1 (en) 2016-03-22 2017-09-28 Bayer Pharma Aktiengesellschaft 1h-benzo[de]isoquinoline-1,3(2h)-diones
EP3338780A1 (de) 2016-12-20 2018-06-27 Bayer Pharma Aktiengesellschaft Verwendung von chymaseinhibitoren zur behandlung von endometriose, post-operativer fibrose und erkrankungen die durch fibrosebildung gekennzeichnet sind
WO2018197333A1 (en) 2017-04-27 2018-11-01 Bayer Aktiengesellschaft Selective adrenoreceptor alpha2c receptor antagonists alone, or in combination with chymase inhibitors for use in the treatment and/or prophylaxis of peripheral artery diseases (pad)
EA202092680A1 (ru) 2018-05-15 2021-04-13 Байер Акциенгезельшафт 1,3-тиазол-2-ил-замещенные бензамиды для лечения заболеваний, ассоциированных с сенситизацией нервных волокон
CN110229067A (zh) * 2019-06-05 2019-09-13 南京焕然生物科技有限公司 一种2-氨基茚制备方法
WO2021000933A1 (zh) * 2019-07-03 2021-01-07 南京明德新药研发有限公司 作为糜酶抑制剂的嘧啶酮类化合物及其应用
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
CN111440141A (zh) * 2020-05-20 2020-07-24 安徽泽升科技有限公司 一种羟甲基取代芳杂环类化合物的制备方法
WO2022135514A1 (zh) * 2020-12-25 2022-06-30 广东东阳光药业有限公司 多取代的尿嘧啶衍生物及其用途
CN114671878B (zh) * 2020-12-25 2023-08-04 广东东阳光药业有限公司 取代的含氮双环化合物及其用途
WO2022135502A1 (zh) * 2020-12-25 2022-06-30 广东东阳光药业有限公司 多取代的尿嘧啶衍生物及其用途
TW202339706A (zh) * 2021-12-06 2023-10-16 美商普萊萃歐治療公司 含醯胺的ｌｏｎｐ１抑制劑化合物、用途及方法
TW202404601A (zh) 2022-04-05 2024-02-01 加拿大商索科普拉健康與人類科學兩合公司 用於選擇性消退血栓性或血栓栓塞性疾病中血栓的凝乳酶抑制劑

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403599B1 (en) * 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
US6114532A (en) 1998-02-03 2000-09-05 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, the preparation thereof, and their use as pharmaceuticals
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
US6458952B1 (en) 1999-05-19 2002-10-01 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
EP1219611A4 (en) 1999-09-03 2003-03-19 Ajinomoto Kk NEW PROCESSES FOR THE PRODUCTION OF OXAZEPINE DERIVATIVES
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
GB0021315D0 (en) * 2000-08-30 2000-10-18 Dainippon Pharmaceutical Co Heterocyclic compounds and intermediates thereof
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
JP2003017508A (ja) 2001-07-05 2003-01-17 Nec Corp 電界効果トランジスタ
AR038536A1 (es) 2002-02-25 2005-01-19 Upjohn Co N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
JP2003342265A (ja) * 2002-05-22 2003-12-03 Senju Pharmaceut Co Ltd トリアゾリジン誘導体およびその医薬用途
US20060079554A1 (en) 2002-12-06 2006-04-13 Barry Peter C Inhibitors of monomine uptake
WO2005018672A1 (ja) * 2003-08-22 2005-03-03 Teijin Pharma Limited キマーゼ阻害剤を有効成分として含有する薬剤
DE102004004928A1 (de) 2004-01-31 2005-08-18 Bayer Healthcare Ag Dibenzoxazepine II
JP5319113B2 (ja) 2004-03-26 2013-10-16 メチルジーン インコーポレイテッド ヒストンデアセチラーゼの阻害剤
US7507748B2 (en) 2004-07-22 2009-03-24 Amgen Inc. Substituted aryl-amine derivatives and methods of use
AU2005321946B2 (en) 2004-12-23 2012-08-16 Deciphera Pharmaceuticals, Llc Enzyme modulators and treatments
CA2606760C (en) 2005-05-04 2014-12-23 Renovis, Inc. Tetrahydronaphthyridine and tetrahydropyrido[4,3-d]pyrimidine compounds and compositions thereof useful in the treatment of conditions associated with neurological and inflammatory disorders and disfunctions
WO2007007161A2 (en) * 2005-07-08 2007-01-18 Orchid Research Laboratories Limited Novel bio-active derivatives
US20080318989A1 (en) 2005-12-19 2008-12-25 Burdick Daniel J Pyrimidine Kinase Inhibitors
WO2007093904A1 (en) 2006-02-14 2007-08-23 Pfizer Products Inc. Benzoxazinone and benzoxazepinone oxazolidinones as antibacterial agents
PE20080209A1 (es) 2006-06-23 2008-05-15 Smithkline Beecham Corp Derivados de glicina como inhibidores de prolil hidroxilasa
US7790756B2 (en) 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
GB0622472D0 (en) 2006-11-10 2006-12-20 Addex Pharmaceuticals Sa Novel heterocyclic derivatives
JP2010519204A (ja) 2007-02-16 2010-06-03 アムジエン・インコーポレーテツド 窒素含有複素環ケトン類およびそれらのｃ−Ｍｅｔ阻害薬としての使用
JP2010523700A (ja) 2007-04-13 2010-07-15 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼインヒビターとして有用なアミノピリミジン
WO2009049112A1 (en) 2007-10-10 2009-04-16 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
EP2205609B1 (de) 2007-10-19 2017-03-29 Boehringer Ingelheim International GmbH Heterocyclus-substituierte piperazino-dihydrothienopyrimidine
WO2009135299A1 (en) * 2008-05-05 2009-11-12 Merck Frosst Canada Ltd. 3, 4 - substituted piperidine derivatives as renin inhibitors
DE102008030091B4 (de) 2008-06-25 2011-03-03 Resprotect Gmbh Uracilderivate und deren Verwendung
RU2011102560A (ru) 2008-06-25 2012-07-27 Дайити Санкио Компани, Лимитед (Jp) Соединение карбоновой кислоты
UA112897C2 (uk) * 2012-05-09 2016-11-10 Байєр Фарма Акцієнгезелльшафт Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань

Also Published As

Publication number Publication date
DK2847190T3 (en) 2016-07-25
EA201790032A1 (ru) 2017-05-31
EP3045456A1 (de) 2016-07-20
AU2013258223B2 (en) 2017-11-09
AR090994A1 (es) 2014-12-30
CN106983751B (zh) 2020-01-07
US20150148340A1 (en) 2015-05-28
US20180256576A1 (en) 2018-09-13
SA113340533B1 (ar) 2015-10-12
CN104395310A (zh) 2015-03-04
CO7131375A2 (es) 2014-12-01
NO3045456T3 (hr) 2018-03-24
JP2015516000A (ja) 2015-06-04
CY1118900T1 (el) 2018-01-10
HK1202873A1 (en) 2015-10-09
JP6367421B2 (ja) 2018-08-01
PH12014502496A1 (en) 2015-01-12
IL253950A0 (en) 2017-10-31
ES2657315T3 (es) 2018-03-02
US9949978B2 (en) 2018-04-24
AU2013258223A1 (en) 2014-11-27
HRP20180125T1 (hr) 2018-02-23
MX357712B (es) 2018-07-20
CL2014003031A1 (es) 2015-03-06
SI2847190T1 (sl) 2016-08-31
IL253950B (en) 2019-07-31
EA030383B1 (ru) 2018-07-31
EP3045456B1 (de) 2017-10-25
CU20140129A7 (es) 2015-02-26
MY181828A (en) 2021-01-08
EP2847190A1 (de) 2015-03-18
US10300062B2 (en) 2019-05-28
HUE035462T2 (en) 2018-05-02
HUE029366T2 (en) 2017-02-28
PT3045456T (pt) 2018-01-30
MX2014013571A (es) 2014-12-08
BR112014028086A2 (pt) 2020-12-01
EP2847190B1 (de) 2016-04-06
RS54901B1 (sr) 2016-10-31
US20170020875A1 (en) 2017-01-26
PT2847190T (pt) 2016-07-14
MX367599B (es) 2019-08-28
CY1119840T1 (el) 2018-06-27
ZA201408146B (en) 2017-01-25
LT3045456T (lt) 2018-02-12
CN106983751A (zh) 2017-07-28
TWI579278B (zh) 2017-04-21
US20170020876A1 (en) 2017-01-26
SI3045456T1 (en) 2018-03-30
CN104395310B (zh) 2017-05-03
EA201492040A1 (ru) 2015-12-30
CA2872906C (en) 2020-08-04
TWI635085B (zh) 2018-09-11
PE20142301A1 (es) 2014-12-19
PH12014502496B1 (en) 2015-01-12
US9481672B2 (en) 2016-11-01
ECSP14026138A (es) 2015-12-31
HRP20160796T1 (hr) 2016-08-12
AU2017265047A1 (en) 2017-12-14
EA031222B1 (ru) 2018-12-28
KR20150016548A (ko) 2015-02-12
IL235438A (en) 2017-08-31
US20200061063A1 (en) 2020-02-27
ES2581537T3 (es) 2016-09-06
JO3290B1 (ar) 2018-09-16
DK3045456T3 (da) 2018-01-29
UY34797A (es) 2013-11-29
JP2017160242A (ja) 2017-09-14
TW201734007A (zh) 2017-10-01
CR20140513A (es) 2014-12-02
RS56784B1 (sr) 2018-04-30
JP6141414B2 (ja) 2017-06-07
TW201406744A (zh) 2014-02-16
KR102083281B1 (ko) 2020-05-29
EA030383B9 (ru) 2018-12-28
WO2013167495A1 (de) 2013-11-14
NZ701700A (en) 2016-09-30
DOP2014000255A (es) 2015-02-27
TN2014000470A1 (en) 2016-03-30
PL2847190T3 (pl) 2016-12-30
UA112897C2 (uk) 2016-11-10
BR112014028086B1 (pt) 2021-09-21
US9949977B2 (en) 2018-04-24
CA2872906A1 (en) 2013-11-14
PL3045456T3 (pl) 2018-03-30
AU2017265047B2 (en) 2019-04-18
SG10202003175QA (en) 2020-05-28

Similar Documents

Publication Publication Date Title
IL253950B (en) Cyclic-converted uracils and their use
HK1203493A1 (en) Substituted azabicycles and use thereof
HK1199023A1 (en) Substituted benzothienylpyrrolotriazines and uses thereof
HK1200822A1 (en) Substituted dipyridylamines and uses thereof
IL239643A0 (en) Converted morphines and their use
EP2888238A4 (en) BENZOCYCLO-OCTYNE COMPOUNDS AND USES THEREOF
IL237068A (en) 1,3-dioxanomorphides and 1,3-dioxanocodides
EP3083606A4 (en) Pyrimidines and use thereof
GB201305277D0 (en) Novel combination and use
HK1210949A1 (en) Combinations and uses thereof
HK1203198A1 (en) Substituted phenylimidazopyrazoles and use thereof
EP2940724A4 (en) FASTENING ELEMENT AND FIXING DEVICE THEREFOR
PT2855506T (pt) Péptido e utilização do mesmo
EP2913325A4 (en) SUBSTITUTED PYRIMIDINE COMPOUND AND APPLICATIONS THEREOF
HK1210809A1 (en) Beta-hexosyl-transferases and uses thereof
IL237400A0 (en) Rhizobacteria and its uses
PL2895751T3 (pl) Śruba i jej zastosowanie
GB201305297D0 (en) Novel agents and uses thereof
HK1207154A1 (en) C1q-adiponectin complex and use thereof c1q-
GB201210667D0 (en) The sleep easy